DGAP-News: CEVEC strengthens team to execute rapid growth strategy

DGAP-News: CEVEC Pharmaceuticals GmbH / Key word(s): Change of
Personnel/Miscellaneous
CEVEC strengthens team to execute rapid growth strategy

14.10.2015 / 08:30

---------------------------------------------------------------------

Press Release

CEVEC strengthens team to execute rapid growth strategy 

  - Dr. Nico Scheer appointed as Vice President Business Development
    Glycoproteins

  - Dr. Hartmut Tintrup appointed as Vice President Business Development
    Gene Therapy and Viruses

  - Headcount increased by 40% since May 2015

Cologne, Germany, October 14, 2015 - CEVEC Pharmaceuticals GmbH (CEVEC),
the expert in the production of tailor-made recombinant glycoproteins and
gene therapy vectors, today announced the expansion and reorganization of
its management team.

Dr. Nico Scheer will join the Company as Vice President Business
Development Glycoproteins as of November 1, 2015. Dr. Scheer will be
responsible for CEVEC's growth strategy in the Company's CAP(R)Go
activities. Dr. Hartmut Tintrup, currently Chief Business Officer, moves to
the position of Vice President Business Development Gene Therapy and
Viruses in which he will be responsible for the growth of CEVEC's CAP(R)GT
business. Both will be reporting to CEO Frank Ubags.

Frank Ubags, Chief Executive Officer of CEVEC Pharmaceuticals GmbH,
commented, "Following our focus on glycoproteins and gene therapy vectors
in May 2015 and the subsequent successful co-operations, we have increased
our overall headcount by 40% and attracted competent, talented people in
the scientific, quality assurance and regulatory business fields. We are
experiencing an exponentially increasing demand for our CAP(R)Go portfolio
in the field of glycoproteins and for our CAP(R)GT technology for the
industrial scale production of gene therapy vectors. With this
strengthening and restructuring of the management team, we are now well
placed to further accelerate the growth of our Company."

"It's an exciting time to join CEVEC, as the Company is poised to take
advantage of significant growth and expansion opportunities to build market
leadership in the production of tailor-made recombinant glycoproteins,"
added Dr. Nico Scheer. "I am delighted to get the opportunity to identify
and form alliances that unlock the full potential of CEVEC's unique
CAP(R)Go Technology."

Prior to joining CEVEC, Dr. Scheer served in different leading management
positions within Artemis Pharmaceuticals GmbH, TaconicArtemis GmbH and
Taconic Biosciences GmbH - most recently as Director Business Development
and Head of tADMET portfolio. Dr. Scheer adds more than 10 years of
experience in business development, portfolio and project management, plus
licensing and partnering activities in the life science industry as well as
a strong scientific background in drug metabolism, molecular biology, and
in vitro technologies. He holds a PhD in Molecular Developmental Biology
and a PMI certified Project Management Professional (PMP).


About CEVEC:

Privately held CEVEC, based in Cologne, Germany, is an expert for the
production of tailor-made recombinant glyco-proteins and gene therapy
vectors. The Company's core technologies, CAP(R)Go and CAP(R)GT are based
on a unique human cellular expression system.

The CAP(R)Go expression platform comprises a portfolio of glyco-optimized
human suspension cell lines for tailor-made glycosylation of recombinant
proteins. The cells are highly efficient for the production of a broad
range of difficult to express glyco-proteins and provide authentic human
post-translational modifications. CAP(R)Go has proven to enhance the
activity, stability and serum half-life of several candidate proteins.

The CAP(R)GT expression platform provides a fully scalable, regulatory
endorsed production system for gene therapy vectors. CAP(R)GT cells grow to
high cell densities and show a broad viral propagation spectrum including
lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV).
Furthermore, CAP(R)GT enables easier scale-up and reduced production costs
when compared to adherent cell culture systems.

Research collaborations with international pharmaceutical and biotechnology
partners followed by licensing agreements for the technology form one
revenue base for CEVEC. In addition, the Company provides contract
manufacturing for the GMP production in CAP(R)Go and CAP(R)GT cells.


Contact:      

<pre>

CEVEC Pharmaceuticals GmbH                 MC Services AG
Frank Ubags                                Anne Hennecke
Chief Executive Officer                    Public Relations
T.:+49 221 46020800                        T.: +49 211 52925222
E.: ubags@cevec.com                        E.: anne.hennecke@mc-services.eu


</pre>

www.cevec.com



---------------------------------------------------------------------

14.10.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


402329 14.10.2015